A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications

Arthritis and Rheumatism

Volumn 52, Issue 8, 2005, Pages 2495-2505

  Holman, Andrew J ^a   Myers, Robin R ^a  

^a Pacific Rheumatology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HYPNOTIC AGENT; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PRAMIPEXOLE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; AUTONOMIC DYSFUNCTION; BECK ANXIETY INDEX; BLOATING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DIARRHEA; DIZZINESS; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HAMILTON SCALE; HEADACHE; HEALTH STATUS; HICCUP; HUMAN; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MICTURITION DISORDER; MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE; MUSCLE SPASM; NAUSEA; PAIN ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; THORAX PAIN; TINNITUS; TREATMENT OUTCOME; URINARY FREQUENCY; URTICARIA; VISUAL ANALOG SCALE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANALGESICS, OPIOID; BENZOTHIAZOLES; DISABLED PERSONS; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PAIN; THIAZOLES; TREATMENT OUTCOME;

EID: 23644458324     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21191     Document Type: Article

References (34)

1. Martinez-Lavin M, Hermosillo AG, Rosas M, Soto ME. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum 1998;41:1966-71.
2. Petzke F, Clauw DJ. Sympathetic nervous system function in fibromyalgia. Curr Rheumatol Rep 2000;2:116-23.
3. Raj SR, Brouillard D, Simpson CS, Hopman WM, Abdollah H. Dysautonomia among patients with fibromyalgia: a noninvasive assessment. J Rheumatol 2000;27:2660-5.
4. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Abnormal sympathovagal balance in men with fibromyalgia. J Rheumatol 2001;28:581-9.
5. Moldofsky H, Scarisbrick P, England R, Smythe J. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 1975; 37:341-51.
6. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999;74:385-98.
7. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003;17:685-701.
8. Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol 2004;61:641-4.
9. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000;24:125-32
10. Dziedzicka-Wasylewska M, Ferrari F, Johnson RD, Mierau J, Rogoz Z, Skuza G, et al. Mechanisms of action of pramipexole: effects on receptors. Rev Contemp Pharmacother 2001;12:1-31.
11. Lin SC, Kaplan J, Burger CD, Fredrickson PA. Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc 1998;73:497-500.
12. Yunus M, Aldag J. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 1996;312:1339.
13. Holman AJ, Neiman RA, Ettlinger RE. Preliminary efficacy of the dopamine agonist, pramipexole for fibromyalgia: the first, open label, multicenter experience. J Musculoskel Pain 2004;12:69-74.
14. Holman AJ. Pramipexole and fibromyalgia: promise and precaution [letter]. J Rheumatol 2003;30:2733.
15. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
16. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire (FIQ): development and validation. J Rheumatol 1991;18:728-33.
17. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-97.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
19. Pincus T, Swearingen C, Wolfe F. Toward a Multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly Health Assessment Questionnaire format. Arthritis Rheum 1999;42:2220-30.
20. Holman AJ. Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind pilot randomized controlled trial (RCT) with 14-week blinded extension [abstract]. Arthritis Rheum 2004;50 Suppl 9;S698.
21. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, et al. Brain dopamine and obesity. Lancet 2001;357:354-7.
22. Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia. Life Sci 1999;65:2269-87.
23. Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, van Tol HH, et al. A D2 class dopamine receptor transactivates a receptor kinase to inhibit NMDA receptor transmission. Neuron 2002;35: 1111-22.
24. Yunus MB. Use of a dopamine agonist in fibromyalgia: where is the evidence? J Clin Rheumatol 2003;9:211-4.
25. Wood PB. Fibromyalgia syndrome: a central role for the hippocampus: a theoretical construct. J Musculoskeletal Pain 2004; 12:19-26.
26. Lopez JF, Akil H, Watson SJ. Neural circuits mediating stress. Biol Psychiatry 1999;46:1461-71.
27. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925-35.
28. Petzke F, Clauw DJ. Sympathetic nervous system function in fibromyalgia. Curr Rheumatol Rep 2000;2:116-23.
29. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002;58 Suppl 1:S1-S8.
30. Lentz MJ, Landis CA, Rothermel J, Shaver JL. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999;26:1586-92.
31. Older SA, Battafarano DF, Danning CL, Ward JA, Grady EP, Derman S, et al. The effects of delta wave sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects: correlation with insulin-like growth factor I. J Rheumatol 1998;25:1180-6.
32. Matinez-Lavin M, Hermosillo AG. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 2000;29:197-9.
33. Krassioukov AV, Furlan JC, Fehlings MG. Autonomic dysreflexia in acute spinal cord injury: an under-recognized clinical entity. J Neurotrauma 2003;20:707-16.
34. Resta O, Rana L, Procacci V, Guido P, Picca V, Scarpelli F. Autonomic dysfunction in normotensive awake subjects with obstructive sleep apnoea syndrome. Monaldi Arch Chest Dis 1998;53:23-9.